Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases)
The development of a new direction in anticancer medical therapy – the use of immune checkpoint inhibitors targeting PD-1/ PD-L1 and CTLA-4 – has significantly changed the approach to tumor treatment in the last few years. The PD1 blocker nivolumab in major registered clinical trials improved overal...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-08-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/6249 |
| _version_ | 1797841658764591104 |
|---|---|
| author | L. Yu. Vladimirova A. Eh. Storozhakova I. L. Popova S. N. Kabanov N. A. Abramova M. A. Teplyakova N. M. Tikhanovskaya K. A. Novoselova A. A. Lyanova L. A. Ryadinskaya V. S. Myagkova F. V. Alieva E. A. Kalabanova Ya. V. Svetitskaya N. Yu. Samaneva A. V. Tishina |
| author_facet | L. Yu. Vladimirova A. Eh. Storozhakova I. L. Popova S. N. Kabanov N. A. Abramova M. A. Teplyakova N. M. Tikhanovskaya K. A. Novoselova A. A. Lyanova L. A. Ryadinskaya V. S. Myagkova F. V. Alieva E. A. Kalabanova Ya. V. Svetitskaya N. Yu. Samaneva A. V. Tishina |
| author_sort | L. Yu. Vladimirova |
| collection | DOAJ |
| description | The development of a new direction in anticancer medical therapy – the use of immune checkpoint inhibitors targeting PD-1/ PD-L1 and CTLA-4 – has significantly changed the approach to tumor treatment in the last few years. The PD1 blocker nivolumab in major registered clinical trials improved overall survival, including in metastatic melanoma, with a favorable toxicity profile. However, its efficacy in patients with brain metastases from melanoma was poorly studied, since the inclusion criteria for most clinical trials do not envisage recruiting such patients. The immune-mediated toxicity of immune checkpoint inhibitors is currently well enough studied. However, cases of cutaneous toxicity are quite rare and present certain difficulties for differential diagnosis and treatment. This article presents two cases of effective nivolumab treatment in patients with generalized BRAFwt and BRAFmut cutaneous melanoma. The first case is of interest due to the presence of brain metastases in the patient. Nivolumab therapy helped achieving complete regression of intracranial metastases with the long-term effect. The second case, in addition to effective treatment, demonstrates a rare manifestation of skin toxicity – vitiligo on the face and upper extremities. |
| first_indexed | 2024-04-09T16:34:52Z |
| format | Article |
| id | doaj.art-d6b80369b6694d488584cf1468b3b89e |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:34:52Z |
| publishDate | 2021-08-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-d6b80369b6694d488584cf1468b3b89e2023-04-23T06:56:56ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-08-0109647410.21518/2079-701X-2021-9-64-745644Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases)L. Yu. Vladimirova0A. Eh. Storozhakova1I. L. Popova2S. N. Kabanov3N. A. Abramova4M. A. Teplyakova5N. M. Tikhanovskaya6K. A. Novoselova7A. A. Lyanova8L. A. Ryadinskaya9V. S. Myagkova10F. V. Alieva11E. A. Kalabanova12Ya. V. Svetitskaya13N. Yu. Samaneva14A. V. Tishina15National Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyNational Medical Research Centre for OncologyThe development of a new direction in anticancer medical therapy – the use of immune checkpoint inhibitors targeting PD-1/ PD-L1 and CTLA-4 – has significantly changed the approach to tumor treatment in the last few years. The PD1 blocker nivolumab in major registered clinical trials improved overall survival, including in metastatic melanoma, with a favorable toxicity profile. However, its efficacy in patients with brain metastases from melanoma was poorly studied, since the inclusion criteria for most clinical trials do not envisage recruiting such patients. The immune-mediated toxicity of immune checkpoint inhibitors is currently well enough studied. However, cases of cutaneous toxicity are quite rare and present certain difficulties for differential diagnosis and treatment. This article presents two cases of effective nivolumab treatment in patients with generalized BRAFwt and BRAFmut cutaneous melanoma. The first case is of interest due to the presence of brain metastases in the patient. Nivolumab therapy helped achieving complete regression of intracranial metastases with the long-term effect. The second case, in addition to effective treatment, demonstrates a rare manifestation of skin toxicity – vitiligo on the face and upper extremities.https://www.med-sovet.pro/jour/article/view/6249immune checkpoint inhibitorsnivolumabmetastatic melanomabrain metastasesimmune-mediated toxicityvitiligo |
| spellingShingle | L. Yu. Vladimirova A. Eh. Storozhakova I. L. Popova S. N. Kabanov N. A. Abramova M. A. Teplyakova N. M. Tikhanovskaya K. A. Novoselova A. A. Lyanova L. A. Ryadinskaya V. S. Myagkova F. V. Alieva E. A. Kalabanova Ya. V. Svetitskaya N. Yu. Samaneva A. V. Tishina Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases) Медицинский совет immune checkpoint inhibitors nivolumab metastatic melanoma brain metastases immune-mediated toxicity vitiligo |
| title | Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases) |
| title_full | Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases) |
| title_fullStr | Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases) |
| title_full_unstemmed | Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases) |
| title_short | Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases) |
| title_sort | some aspects of nivolumab administration in treatment for metastatic melanoma clinical cases |
| topic | immune checkpoint inhibitors nivolumab metastatic melanoma brain metastases immune-mediated toxicity vitiligo |
| url | https://www.med-sovet.pro/jour/article/view/6249 |
| work_keys_str_mv | AT lyuvladimirova someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT aehstorozhakova someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT ilpopova someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT snkabanov someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT naabramova someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT mateplyakova someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT nmtikhanovskaya someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT kanovoselova someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT aalyanova someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT laryadinskaya someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT vsmyagkova someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT fvalieva someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT eakalabanova someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT yavsvetitskaya someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT nyusamaneva someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases AT avtishina someaspectsofnivolumabadministrationintreatmentformetastaticmelanomaclinicalcases |